Respiratory System Neoplasm

Neratinib-resistant cell lines were established by stepwise escalation method and high concentration method in breast cancer cell line BT-474 and lung cancer cell line H2170 with HER2 amplification. E… (full text at CIViC)

PMID 31856375 · Takeda et al., 2020 · Open in CIViC

In this phase II basket trial, 18 patients with advanced HER2-mutant lung adenocarcinomas were enrolled to receive ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression.… (full text at CIViC)

PMID 29989854 · Li et al., 2018 · Open in CIViC

Ninety patients (pre-treated with a median of 2 lines of therapy) with Non-Small Cell Lung Cancer harbouring HER2 exon 20 insertion mutations were treated with poziotinib. The ORR was 27.8% (95% CI, 1… (full text at CIViC)

PMID 34843401 · Le et al., 2022 · Open in CIViC

Eighty pre-treated patients with Non-Small Cell Lung Cancer harbouring HER2 exon 20 insertions were treated with poziotinib. The ORR Was 39% (95% CI, 28%-50%), and 80% of the patients had a tumour red… (full text at CIViC)

PMID 36958688 · Cornelissen et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In an in vitro study, Ba/F3 cells expressing ERBB2 G776insV_G/C mutation demonstrated decreased sensitivity to erlotinib treatment (IC50: 0.28 umol/L vs. 0.009 umol/L) compared to Ba/F3 cells expressi… (full text at CIViC)

PMID 16818618 · Shimamura et al., 2006 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration b… (full text at CIViC)

PMID 25899785 · Kris et al., 2015 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

The authors report a case series where one patient with lung adenocarcinoma harbored ERBB2 variant H878Y (exon 21). Case 2, a 59-year-old male, received Trastuzumab deruxtecan (T-DXd) (5.0 mg/kg once … (full text at CIViC)

PMID 40873587 · Meng et al., 2025 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment. All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions. In pat… (full text at CIViC)

PMID 26598547 · Mazières et al., 2016 · Open in CIViC

In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC)

PMID 41104928 · Le et al., 2025 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

Osimertinib was effective in achieving a partial response in a patient with stage IV non-small cell lung cancer metastasis in the brain harboring ERBB2 exon 19 c.2262_2264delinsTCC, p.(L755P) variant.… (full text at CIViC)

PMID 37197637 · Jonsdottir et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In the multicohort phase 1b Beamion LUNG-1 trial (NCT04886804) of zongertinib in HER2-mutant NSCLC, three cohorts were evaluated by mutation type and prior therapy. In cohort 1 (n = 75; HER2-TKD mutat… (full text at CIViC)

PMID 40293180 · Heymach et al., 2025 · Open in CIViC

In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A… (full text at CIViC)

PMID 25899785 · Kris et al., 2015 · Open in CIViC

In a phase 2 trial, 152 previously-treated metastatic NSCLC patients harboring mutations in ERBB2 (HER2) were treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 m… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among thirty… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

Cell proliferation analysis of NIH 3T3 cells harboring the S310Y variation exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A kinase-inacti… (full text at CIViC)

PMID 22908275 · Greulich et al., 2012 · Open in CIViC

In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

The authors report a case series where two patients with lung adenocarcinoma tumors harbored ERBB2 variant V659E (exon 17). Both cases achieved partial response to Trastuzumab deruxtecan (T-DXd). The… (full text at CIViC)

PMID 40873587 · Meng et al., 2025 · Open in CIViC

A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion. Afatinib monotherapy resulted… (full text at CIViC)

PMID 26559459 · Li et al., 2015 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In an open-label, multicenter, multicohort phase 1–2 study of non-small cell lung carcinoma (NCT05099172; total n = 209), single-agent sevabertinib 20 mg BID demonstrated clinically meaningful activit… (full text at CIViC)

PMID 41104928 · Le et al., 2025 · Open in CIViC

Two lung cancer cell lines, 11_18 and Ma-24, were found to have significantly increased growth when treated with heregulin (HRG)‐α compared to other growth factors. Pertuzumab was found to significan… (full text at CIViC)

PMID 17627612 · Sakai et al., 2007 · Open in CIViC

Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Prote… (full text at CIViC)

PMID 26689995 · Umelo et al., 2016 · Open in CIViC